New Alzheimer Drug Aducanumab Faces Controversy
The June 2021 announcement that Aducanamab –known by its shelf name Aduhelm™ -was granted FDA-accelerated approval as a treatment for Alzheimer's disease created a flurry of excitement in families whose loved ones have been diagnosed with the terminal disease. Aduhelm is considered the first therapy to demonstrably remove amyloid plaques, one of the notorious primary [...]